Stay updated on Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The study record is displayed with its expanded-access details, including the tucatinib intervention, eligibility information, sponsor, and record dates.
    Difference
    26%
    Check dated 2026-11-08T02:00:30.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the study record content remains unavailable on the 403 page.
    Difference
    0.2%
    Check dated 2026-10-31T22:07:26.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    A site-wide NIH notice appears above the page navigation, announcing a terminology transition from “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T22:27:27.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer displays revision v3.7.2 instead of v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-17T22:31:46.000Z thumbnail image
  5. Check
    31 days ago
    Change Detected
    Summary
    The site's footer revision changed from v3.7.0 to v3.7.1; the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T22:21:37.000Z thumbnail image
  6. Check
    52 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error page instead of the study content. The error page includes the site chrome (header/footer) and blocks access to the study record.
    Difference
    13%
    Check dated 2026-09-19T21:59:10.000Z thumbnail image

Stay in the know with updates to Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.